Compare NSP & AGMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NSP | AGMB |
|---|---|---|
| Founded | 1986 | 2017 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 819.5M | 677.9M |
| IPO Year | 1996 | N/A |
| Metric | NSP | AGMB |
|---|---|---|
| Price | $31.73 | $10.71 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $47.67 | $32.00 |
| AVG Volume (30 Days) | ★ 816.6K | 182.7K |
| Earning Date | 04-30-2026 | 06-16-2026 |
| Dividend Yield | ★ 8.30% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $6,812,000,000.00 | N/A |
| Revenue This Year | $3.45 | N/A |
| Revenue Next Year | $6.95 | $33.33 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 3.51 | N/A |
| 52 Week Low | $18.57 | $9.00 |
| 52 Week High | $80.45 | $17.45 |
| Indicator | NSP | AGMB |
|---|---|---|
| Relative Strength Index (RSI) | 67.21 | 42.95 |
| Support Level | $31.00 | $9.82 |
| Resistance Level | $39.86 | $12.06 |
| Average True Range (ATR) | 1.75 | 1.23 |
| MACD | 0.47 | 0.17 |
| Stochastic Oscillator | 96.55 | 56.21 |
Insperity Inc is a company that provides a wide range of human resources and business solutions designed to help businesses improve their performance. Small and midsize enterprises are the company's primary target customers. Majority of the company's products are offered through the company's Workforce Optimization and Workforce Synchronization solutions, which comprise various human resource functions, such as payroll and employment administration, employee benefits and compensation, government compliance, performance management, training and development services, and human capital management. The company generates all of its revenue in the United States.
AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Its product candidates are designed to target established pathways and utilize validated modalities, with a focus on addressing limitations associated with prior treatment approaches. The company's pipeline includes small molecule and antibody product candidates aimed at targets associated with fibrotic diseases. Key candidates include Ontunisertib (AGMB-129) and AGMB-447.